Skip to main content

baricitinib

Generic: BARICITINIB·Brand: BARICITINIB, OLUMIANT, Olumiant

baricitinib: developed by 1 company · 33 clinical trials tracked · 1 FDA decision.

baricitinib evidence translation

What we can confirm

1 FDA record · 33 tracked trials

What it means

Source-backed records connect baricitinib to LLY; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could baricitinib → LLY affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 1 study sponsors

Related indications

In collaboration with Incyte Corporation, for the treatment of adults with moderately to severely active rheumatoid arthritis after treatment with one or more tumor necrosis factor (TNF) blockers that did not work well enough or could not be tolerated; moderate to severe atopic dermatitis; severe alopecia areata; and for the treatment of hospitalized adults with COVID-19 who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation.for the treatment of adults with moderately to severely active rheumatoid arthritis after treatment with one or more TNF blockers that did not work well enough or could not be tolerated; moderate to severe atopic dermatitis; severe alopecia areata; and for the treatment of hospitalized adults with COVID-19 who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation.AlopeciaAlopecia AreataAtopic DermatitisCOVID-19Chronic Kidney DiseasesDiabetes Mellitus, Type 1
Development Pipeline (2)
CompanyPhase
ELI LILLY & Co (LLY)
In collaboration with Incyte Corporation, for the treatment …
Approved
ELI LILLY & Co (LLY)
for the treatment of adults with moderately to severely acti…
Approved
Clinical Trials (33)showing 10 most recent

A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)

NCT07543458·Phase 3
Not yet recruiting

Primary endpoint: Progression to severe dengue/critical dengue

InterventionalRandomizedquadruple8,800 targetStarted 2026-10Completion 2031-0718 sites · Bangladesh, Brazil, Colombia, Indonesia…Oxford University Clinical Research Unit, Vietnam

Baricitinib Curative Repression of HIV-1

NCT07209267·Phase 2
Not yet recruiting

Primary endpoint: Time to restart ART

Interventionalopen35 targetStarted 2026-10Completion 2028-012 sites · United StatesEmory University

A Phase IIa, Single-Site, Open-Label Trial of Baricitinib in Patients With Cardiac Sarcoidosis

NCT06868381·Phase 2·LLY
Not yet recruiting

Primary endpoint: Proportion of patients with resolution of cardiac FDG uptake on PET-CT

Interventionalopen10 targetStarted 2026-04Completion 2028-121 site · United StatesStanford University

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged ≥1 to <36 Years

NCT07222332·Phase 3·LLY
Recruiting

Primary endpoint: Change from Baseline in C-peptide Area Under the Curve (AUC)

InterventionalRandomizeddouble300 targetStarted 2026-02Completion 2028-0750 sites · Australia, Belgium, Brazil, Canada…Eli Lilly and Company

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years

NCT07222137·Phase 3·LLY
Recruiting

Primary endpoint: Time from Baseline to Diagnosis of Stage 3 Type 1 Diabetes

InterventionalRandomizeddouble150 targetStarted 2026-01Completion 2031-0750 sites · Australia, Belgium, Brazil, Canada…Eli Lilly and Company

Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica - JADORE-BARI Study

NCT07279688·Phase 3
Recruiting

Primary endpoint: Following of the Polymyalgia Rheumatica Activity score

InterventionalRandomizedtriple140 targetStarted 2025-12Completion 2029-0623 sites · FranceUniversity Hospital, Brest

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (REVERSE-LC)

NCT06631287·Phase 3·VALN
Recruiting

Primary endpoint: CNS-Vital Signs Global Cognitive Index

InterventionalRandomizedquadruple550 targetStarted 2024-10Completion 2027-077 sites · United StatesWes Ely

A Pilot Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

NCT06240351·Phase 4
Active, not recruiting

Primary endpoint: 30% Change in Lichen Planopilaris Activity (LPPAI) Scores

Interventionalopen15 targetStarted 2024-04Completion 2027-091 site · United StatesUniversity of Alabama at Birmingham

Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease

NCT05237388·Phase 2
Completed

Primary endpoint: Percent change in albuminuria (UACR)

InterventionalRandomizeddouble8 enrolledStarted 2023-04Completion 2026-041 site · United StatesDuke University

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

NCT05723198·Phase 3·LLY
Recruiting

Primary endpoint: Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) ≤20

InterventionalRandomizeddouble595 targetStarted 2023-02Completion 2033-0950 sites · Argentina, United StatesEli Lilly and Company
FDA Decisions1 records
Approval(LLY)FDA ↗
NDA207924Type 1 - New Molecular EntityStandardOralTablet

Frequently asked questions

Who is developing baricitinib?

baricitinib is being developed by ELI LILLY & Co.

How many clinical trials involve baricitinib?

BioSniper tracks 33 clinical trials involving baricitinib.

What is baricitinib's latest FDA decision?

The most recent tracked FDA decision for baricitinib is Approval, dated May 31, 2018.